Brief: GenSight Biologics Says Clinically Meaningful Vision Improvement Maintained 4 Years After One-Time LUMEVOQ Treatment

Gensight Biologics SA

24/01/2022 06:41

Jan 24 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS REPORTS CLINICALLY MEANINGFUL VISION
IMPROVEMENT IS MAINTAINED 4 YEARS AFTER ONE-TIME TREATMENT WITH
LUMEVOQ GENE THERAPY
    * REVIEW OF EUROPEAN MARKETING AUTHORISATION APPLICATION FOR
LUMEVOQ IS ONGOING, WITH DECISION FROM CHMP EXPECTED IN Q4 2022
    * LEBER HEREDITARY OPTICAL NEUROPATHY (LHON) SUBJECTS
TREATED WITH
LUMEVOQ CONTINUED TO EXPERIENCE SIGNIFICANTLY IMPROVED VISION
FOUR YEARS AFTER A SINGLE INJECTION OF GENE THERAPY
    * FINDINGS COME FROM RESTORE (CLIN06), LONG-TERM FOLLOW-UP
STUDY

Source text for Eikon:  ID:nBw4QxS8pa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))